The selective serotonin reuptake inhibitor paroxetine, but not fluvoxamine, decreases methamphetamine conditioned place preference in mice

Current Neuropharmacology

Volumn 9, Issue 1, 2011, Pages 68-72

  Takamatsu, Y ^a   Yamamoto, H ^a   Hagino, Y ^a   Markou, A ^b   Ikeda, K ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Conditioned place preference; Fluvoxamine; Methamphetamine; Mice; Paroxetine; Serotonin transporter

Indexed keywords

FLUVOXAMINE; METHAMPHETAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG TREATMENT FAILURE; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE;

EID: 79953035864     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015911795017236     Document Type: Article

References (29)

1. United Nations International Drug Control Programme. World drug report 2005. Oxford University Press: New York, 2005.
2. Ujike, H. Stimulant-induced psychosis and schizophrenia: the role of sensitization. Curr. Psychiatry Rep., 2002, 4, 177-184.
3. National Institute on Drug Abuse. Methamphetamine abuse and addiction (Research report series, NIH pub. no. 98-4210). National Institute on Drug Abuse: Bethesda, 2002.
4. Sora, I.; Wichems, C.; Takahashi, N.; Li, X.F.; Zeng, Z.; Recay, R.; Lesch, K.P.; Murphy, D.L.; Uhl, G.R. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl. Acad. Sci. USA, 1998, 95, 7699-7704.
5. Rocha, B.A.; Fumagalli, F.; Gainetdinov, R.R.; Jones, S.R.; Ator, R.; Giros, B.; Miller, G.W.; Caron, M.G. Cocaine self-administration in dopamine-transporter knockout mice. Nat. Neurosci., 1998, 1, 132-137.
6. Sora, I.; Hall, F.S.; Andrews, A.M.; Itokawa, M.; Li, X.F.; Wei, H.B.; Wichems, C.; Lesch, K.P.; Murphy, D.L.; Uhl, G.R. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl. Acad. Sci. USA, 2001, 98, 5300-5305.
7. Shen, H.W.; Hagino, Y.; Kobayashi, H.; Shinohara, K.; Ikeda, K.; Yamamoto, H.; Yamamoto, T.; Lesch, K.P.; Murphy, D.L.; Hall, F.S.; Uhl, G.R.; Sora, I. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in micelacking dopamine and/or serotonin transporters. Neuropsychopharmacology, 2004, 29, 1790-1799.
8. Takamatsu, Y.; Yamamoto, H.; Ogai, Y.; Hagino, Y.; Markou, A.; Ikeda, K. Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice. Ann. N.Y. Acad. Sci., 2006, 1074, 295-302.
9. Hoffman, D.C.; Beninger, R.J. Preferential stimulation of D1 or D2 receptors disrupts food-rewarded operant responding in rats. Pharmacol. Biochem. Behav., 1989, 34, 923-925.
10. Ide, S.; Minami, M.; Satoh, M.; Uhl, G.R.; Sora, I.; Ikeda, K. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology, 2004, 29, 1656-1663.
11. Stanton, T.; Bolden-Watson, C.; Cusack, B.; Richelson, E. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistamines. Biochem. Pharmacol., 1993, 45, 2352-2354.
12. Fryer, J.D.; Lukas, R.J. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J. Neurochem., 1999, 72, 1117-1124.
13. Maertens, C.; Droogmans, G.; Verbesselt, R.; Nilius, B. Block of volume-regulated anion channels by selective serotonin reuptake inhibitors. Naunyn Schmiedebergs Arch. Pharmacol., 2002, 366, 158-165.
14. Pariante, C.M.; Makoff, A.; Lovestone, S.; Feroli, S.; Heyden, A.; Miller A.H.; Kerwin, R.W. Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br. J. Pharmacol., 2001, 134, 1335-1343.
15. Finkel, M.S.; Laghriss-Thode, F.; Pollock, B.G.; Rong, J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol. Bull., 1996, 32, 653-658.
16. Kobayashi, T.; Washiyama, K.; Ikeda, K. Inhibition of G proteinactivated inwardly rectifying K+ channels by the antidepressant paroxetine. J. Pharmacol. Sci., 2006, 102, 278-287.
17. Kobayashi, T.; Washiyama, K.; Ikeda, K. Inhibition of G proteinactivated inwardly rectifying K+ channels by fluoxetine (Prozac). Br. J. Pharmacol., 2003, 139, 1119-1128.
18. Kobayashi, T.; Washiyama, K.; Ikeda, K. Inhibition of G proteinactivated inwardly rectifying K+ channels by various antidepressant drugs. Neuropsychopharacology, 2004, 29, 1841-1851.
19. + (GIRK) channels and functional couplings of the opioid receptors with the GIRK1 channel. Ann. N.Y. Acad. Sci., 1996, 801, 95-109.
20. + channel. Biochem. Biophys. Res. Commun., 1995, 208, 302-308.
21. + (GIRK) channel. Mol. Brain. Res., 1997, 45, 117-126.
22. North, R.A. Drug receptors and the inhibition of nerve cells. Br. J. Pharmacol., 1989, 98, 13-28.
23. Reuveny, E.; Slesinger, P.A.; Inglese, J.; Morales, J.M.; Iniguez- Lluhi, J.A.; Lefkowitz, R.J.; Bourne, H.; Jan, Y.; Jan, L.Y. Activation of the cloned muscarinic potassium channel by G protein βγ subunits. Nature, 1994, 370, 143-146.
24. + channels. Nat. Neurosci., 1999, 2, 1091-1097.
25. Lewohl, J.M.; Wilson, W.R.; Mayfield, R.D.; Brozowski, S.J.; Morrisett, R.A.; Harris, R.A. G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action. Nat. Neurosci., 1999, 2, 1084-1090.
26. Kobayashi, T.; Washiyama, K.; Ikeda, K. Inhibition of G proteinactivated inwardly rectifying K+ channels by ifenprodil. Neuropsychopharmacology, 2006, 31, 516-524.
27. Suzuki, T.; Kato, H.; Tsuda, M.; Suzuki, H.; Misawa, M. Effects of the non-competitive NMDA receptor antagonist ifenprodil on the morphine-induced place preference in mice. Life Sci., 1999, 64, 151-156.
28. Morgan, A.D.; Carroll, M.E.; Stoffel, M.; Wickman, K. Decreased cocaine self-administration in Kir3 potassium channel subunit knockout mice. Neuropsychopharacology, 2003, 28, 932-938.
29. Ago, Y.; Harasawa, T.; Itoh, S.; Nakamura, S.; Baba, A.; Matsuda, T. Antidepressant-like effect of coadministration of sulpiride and fluvoxamine in mice. Eur. J. Pharmacol., 2005, 520, 86-90.